<SEC-DOCUMENT>0001628280-22-017744.txt : 20220622
<SEC-HEADER>0001628280-22-017744.hdr.sgml : 20220622
<ACCEPTANCE-DATETIME>20220622073119
ACCESSION NUMBER:		0001628280-22-017744
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220622
FILED AS OF DATE:		20220622
DATE AS OF CHANGE:		20220622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		221030002

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk06x22x2022.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2d1379537f714b9b86dc7e5c434c248d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of June, 2022.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58; ____</font></div><div><font><br></font></div><div style="margin-bottom:11.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </font></div><div style="margin-bottom:11.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58; ____ </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INCORPORATION BY REFERENCE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1 of this Form 6-K of Cybin Inc. (the &#34;Company&#34;) is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-259994) of the Company, as amended or supplemented.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 22, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="fy2022earningspr-062222fin.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated June 22, 2022</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fy2022earningspr-062222fin.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i283f403f4f624179a26d7ed915172ea3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:78.05pt;padding-right:78.05pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:130px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.25pt;text-align:justify"><font><br></font></div><div style="margin-top:4.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights</font></div><div style="margin-top:4.6pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">- Company reiterates key pipeline and strategic milestones for 2022 &#8211;</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8211; June 22, 2022 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">NEO&#58;CYBN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) (</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">NYSE American&#58;CYBN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a biopharmaceutical company focused on progressing &#8220;Psychedelics to Therapeutics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;, today reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights.  The Company also reiterated its anticipated pipeline and strategic milestones for the remainder of 2022.  </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8220;Cybin made important progress across the board in recent months, accelerating both our pipeline of proprietary investigational psychedelic-based treatments and strategic partnership programs. Our successful preclinical work has set the foundation for a seamless transition to in-human trials,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin. &#8220;Over a very short time horizon, we have evolved into a multi-program clinical-stage company, which marks the dedication of the Cybin team to developing improved treatment options for mental health conditions.&#8221;</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recent Business and Pipeline Highlights&#58; </font></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:14.15pt">Announced U.S. Institutional Review Board (&#8220;IRB&#8221;) approval for its first-in-human Phase 1&#47;2a trial of CYB003 in major depressive disorder (&#8220;MDD&#8221;). </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company received IRB approval less than two weeks after submitting an Investigational New Drug (&#8220;IND&#8221;) application to the U.S. Food and Drug Administration. The Company expects to initiate the Phase 1&#47;2a study in mid-2022 pending IND approval with a potential interim data readout expected at the end of 2022. </font></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:14.15pt">Accelerated clinical development of CYB004 for the potential treatment of anxiety disorders through the planned acquisition of a Phase 1 study from Entheon Biomedical Corp. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Entheon</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The CYB004-E Phase 1 study is currently underway at the Centre for Human Drug Research in the Netherlands. The study is evaluating the pharmacokinetics (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">PK</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;) and pharmacodynamics of intravenous N,N-dimethyltryptamine (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">DMT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;) in 50 healthy volunteers who smoke tobacco.  This is the largest Phase 1 DMT </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">clinical study conducted to date. The study is expected to provide dose optimization and safety data to guide the clinical path forward for CYB004, the Company&#8217;s deuterated DMT molecule, and will replace the previously planned CYB004 pilot study. Preclinical data for CYB004 announced in April 2022 showed significant advantages over inhaled and intravenous DMT, including improved bioavailability, longer duration of effect, and rapid onset of effect and low variability. </font></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:14.15pt">Strengthened the Company&#8217;s IP portfolio with an international patent application for CYB004. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">In February 2022, Cybin was granted a patent by the U.S. Patent and Trademark Office covering new chemical entity claims for CYB004 and various deuterated forms of DMT and 5-MeO-DMT until 2041. Cybin also announced the publication of an international patent application by the World Intellectual Property Organization covering inhalation delivery methods for multiple psychedelic molecules, including CYB004. </font></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:14.5pt">Reported positive preliminary data from a pilot study of Kernel Flow</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">, confirming Flow&#8217;s ability to successfully measure psychedelic effects on the brain. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Flow is a wearable neuroimaging technology device that can quantify brain activity in real time during a psychedelic experience with the potential to support data-driven, personalized psychedelic treatments. These pilot data from an ongoing feasibility study suggested that Flow measurements confirmed changes in functional connectivity after ketamine dosing, which persisted for several days after administration. The pilot data also validated the design of the ongoing Phase 1 Flow feasibility study.</font></div><div style="margin-top:12.6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:14.15pt">Publication of peer-reviewed journal article in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:133%">Frontiers in Psychology</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> introducing EMBARK, Cybin&#8217;s model of psychedelic-assisted psychotherapy. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The EMBARK psychotherapy model will be used to support patients in upcoming clinical trials assessing CYB003 and CYB004 in MDD, alcohol use disorder (&#8220;AUD&#8221;) and anxiety disorders. The Company has compiled a team of 28 expert faculty and advisors from leading universities and psychedelic research and training organizations for the EMBARK program.  </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Upcoming Pipeline and Strategic Milestones&#58;</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company expects to achieve the following milestones across its pipeline and partnership programs&#58; </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CYB003&#58;  Deuterated psilocybin analog for the potential treatment of MDD and AUD</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">The Company expects to initiate its Phase 1&#47;2a placebo-controlled clinical trial of CYB003 in up to 32 MDD patients in the coming weeks. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">The Company plans to report initial safety and PK data from the Phase 1&#47;2a study in Q4 CY2022.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CYB004&#58;  Deuterated DMT for the potential treatment of anxiety disorders</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">The previously announced planned acquisition of a Phase 1 DMT study from Entheon is expected to close in the coming weeks subject to the completion of certain closing conditions and obtaining all necessary approvals.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CYB005&#58;  Phenethylamine derivative for the potential treatment of neuroinflammation </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cybin plans to report preclinical data for CYB005 in Q3 CY2022 at which time the Company expects to nominate a candidate and complete its assessment of the potential path forward for this candidate, including whether it be internally or by way of potential third party partners. </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Kernel Flow</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">The Phase 1 Flow feasibility study is underway. This is a four-week study assessing the participant&#8217;s experience wearing Flow, as well as brain activity, following the administration of ketamine.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8220;We gain confidence every day in our ability to create a true paradigm shift in the way mental health conditions are understood and treated.  By working to develop treatment options that can potentially offer improved efficacy, greater remission rates, and longer duration of effects, we have the potential to provide patients and providers with a new standard of care.  We look forward to continued momentum and sharing meaningful data readouts later this year,&#8221; Drysdale continued.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Fiscal Year 2022 Financial Highlights&#58;</font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cash and cash equivalents totaled to C$53.6 million as of March 31, 2022.   </font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cash-based operating expenses totaled C$13.0 million for the quarter ended March 31, 2022, of which C$3.8 million were one-time, non-recurring costs. Non-cash expenses totaled C$5.1 million for a net loss of C$18.1 million.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cash-based operating expenses totaled C$45.8 million for the year ended March 31, 2022, of which C$11.6 were one-time, non-recurring costs. Non-cash expenses totaled C$21.8 million for a net loss of C$67.6 million.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cash flows used in operating activities were C$9.7 million for the quarter ended March 31, 2022 of which C$1.4 million were one-time, non-recurring costs.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Cash flows used in operating activities were C$45.2 million for the year ended March 31, 2022 of which C$10.7 million were one-time, non-recurring costs.</font></div><div style="margin-bottom:12pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;Our financial position remains strong.  Despite the overall softness in the markets, we are pleased with our industry leadership position and remain confident that we are on the right path forward to progress psychedelics into therapeutics,&#8221; concluded Drysdale.</font></div><div style="margin-bottom:12pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Additional non-cash consideration in the amount of C$4,655.29 is being issued to the previous shareholders of Adelia Therapeutics Inc. in respect of the achievement of a previously announced milestone on April 1, 2022.</font></div><div style="margin-top:12.6pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Cybin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding sharing additional data later this year, the Company&#8217;s CYB003 Phase 1&#47;2a trial in mid-2022 and anticipated results, the potential closing of the Entheon acquisition, statements regarding the Company&#8217;s Phase 1 DMT clinical study for CYB004 and anticipated results, the Company&#8217;s plan to report interim safety and PK data from the Phase 1&#47;2a study in Q4 CY2022, the Company&#8217;s statements regarding its preclinical data for CYB005 and partnering opportunities, statements regarding the Phase 1 Flow feasibility study and expected results, statements regarding the EMBARK psychotherapy model and anticipated results and the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. </font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the COVID-19 pandemic on the Company's operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in the Company's management's discussion and analysis for the year ended March 31, 2022, and the Company&#8217;s annual  information form for the year ended March 31, 2022, which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.05pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">are available under the Company's profile on </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sedar.com</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">and with the U.S. Securities and Exchange Commission on EDGAR at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Although the forward- looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font style="font-family:'Arial',sans-serif;font-size:13.5pt;font-weight:400;line-height:139%"></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Leah Gibson</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Vice President, Investor Relations &#38; Strategic Communications</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> &#8211; or &#8211; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">media&#64;cybin.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI* &_6O)M<_:D^$WA[Q -$U#Q[
MH\.I[_*:(3;PC9QAW4%4]\D5\:?ML?MG7?B;4K_P%X#U)K70X&:'4]6M9,->
M..&AC8=(QT)'WOI][XEV_P -?99?PZ\12]KB).-]DM_G<\^KB^1\L5<_?>WN
M([B%)8G62-U#*ZG(8'H0?2IZ\2_8UU"\U+]F/X?37LC23K8>4&DZ[$E=$_\
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MD;?\M)>D:?BY4?C7X?ZIJESK6J7FHWLS7%]>3-<3RMU>1B68_F:_0G_@I_\
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M#W[*9^,'B)?%_B:U;_A#-+GQ'!(O&I3J<[/>-?XO7[O]ZOU,CC6%%55"JHP
M.@%?,9]F[A_LN'>O5KIY([<-A[^_/Y'XV?M??#/2OA/\?O$.A:)"MKI!6&\M
MK=/NPB5 Q09[ [L>U>-5[]^W=X@C\0?M0>+C"VZ.R6VL?]TI"FX?F6KP#^*O
MJ\ YO"TG/=Q5_N.&K;G?+W9^R'[%LIF_9=^'['M8LGX+-(!_*O;E^]7B_P"Q
MS9FQ_9A^'L9X)TT2?]].S?UKVBOQ[&?[S4_Q/\V>]3^!>B/R7_X*'>*_^$D_
M:6U2S63=#HUC;6*?[)*^:WZR5\TY%=W\>/$?_"6_&KQSK&[<MSK-T4/^PLI5
M?T5:X6OV+ TO8X6E3[)??;4\&K*\W+S8445;T?2+WQ!JMGIFFVLEWJ%[,MO;
MV\:Y>61CA0/Q-=[?(KR,CJ_@_P#!_P 1?&[QM:^&?#=OYD\GSSW<F?)LXAUE
MD(Z#T'4G@5^M'[/_ .S3X3_9[T%;;1[=;O69D OM8N%'GW#=P/[B9Z*/QR>:
MA_9C_9]TO]GOX=V^E1B.XUZ\"7&JWZCF>;'W0?[B9PH_'JU>RY&#SBORC.,V
MGC9NG3=H+\?-GN4*"IJ[W_(?1117S9V%2:".[ADAEC66&12C(ZY# \$$'J*_
M'?\ ;"^"\'P1^-.I:7IT7E:%J2#4=-3^%(G)#1#_ '7# >VVOV/8]<5\!_\
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M.]E$-O:PKEW9N@_Q/:OTF^!?_!/'P;X0T:VO?']LOBGQ!(@>6V:1A96S'^!
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M[B5_[J*"S'\A5[O7S7^WQ\3!\/?V>]7LH)?+U'Q$ZZ3 JM\VU\F4_3RU8?\
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M-$"[#8:3:V[+_M+$H;]<UV#+2(JJJ@=!3^M?@TVYS<WU=SZ=:"T444 %%%%
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M>U'UI.]?CF(Q%3%575J/5_U8^@A!07*@:ORR_P""COQ57QK\9K?PM:2[]/\
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MBBBN U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:*
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MQ#FG-_L=%_XG^G^9Z.%H_;E\B2BBBOA3T@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YU
M_::_8[\/?M%2V^J'4)-!\36L7DQZE#&)$FB!)$<L>1NP2V&!!&X]:\8^%O\
MP3&L='\117_C?Q(FOZ;;R;TTRQMV@2?'02LS$[?4+U]:^[=O%+7HTLTQE&E[
M"G-J/RNO1[F#H4Y/F:U*FGZ?;:38V]E96\=G9VZ"**"%0J1H!@  < "KU%%>
M=N;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
